Achillion Pharma (ACHN) Tops Q1 EPS by 1c

Achillion Pharma (NASDAQ: ACHN) reported Q1 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14).

Update of HCV Clinical Program

• Phase 2a randomized, open-label study to evaluate the safety, pharmacokinetics and efficacy of the combination of AL-335, odalasvir (ACH-3102), and simeprevir in treatment-naïve subjects with genotype 1 chronic hepatitis CThe Janssen sponsored phase 2a clinical trial evaluating all-oral regimens for durations of eight weeks and less remains ongoing. This trial is evaluating a triplet regimen, consisting of odalasvir, AL-335, and simeprevir, for durations of eight and six weeks, as well as a doublet regimen, consisting of odalasvir and AL-335, for eight weeks. Top line results from this study are expected to be released in the third quarter of the year.
• Phase 2b, multicenter, randomized, open-label study to investigate the efficacy, safety and pharmacokinetics of different treatment regimens of AL-335, odalasvir, and simeprevir in treatment-naive and treatment-experienced subjects with chronic hepatitis C virus genotype 1, 2, 3, 4, 5, and 6 infection, with and without cirrhosisJanssen’s planned global phase 2b clinical trial is expected to begin enrolling patients in the third quarter of 2016. This phase 2b clinical trial is designed to evaluate two regimens, a triplet (odalasvir, AL-335, and simeprevir) regimen and a doublet regimen (odalasvir and AL-335), for treatment durations of six and eight weeks in treatment-naïve and treatment-experienced patients with genotypes 1 - 6 HCV, including those patients with or without cirrhosis This trial is expected to enroll approximately 400 patients.

For earnings history and earnings-related data on Achillion Pharma (ACHN) click here.

You May Also Be Interested In

• Humana (HUM) surges on Q1 beat, reiterated adjusted earnings outlook
• Hasbro (HAS) brand strength sees earnings top expectations
• Hilton hikes 2024 earnings outlook as Q1 results beat expectations, shares up